Back to touchmedicalmedia.com

Delivering medical education for a global audience delivered by expert faculty.
touchIME
Read Time: < 1 min

NEW Partnership with Society of Endometriosis and Uterine Disorders (SEUD)

Copy Link
Published Online: Nov 9th 2023
Article:

touchENDOCRINOLOGY is proud to partner with the Society of Endometriosis and Uterine Disorders (SEUD)

The aim of the Society of Endometriosis and Uterine Disorders (SEUD) is to provide an international scientific platform supporting better management of benign gynecological diseases and related uterine dysfunctions.

SEUD’s objective is to focus attention on a group of diseases that negatively affect womens’ health and fertility, including endometriosis, adenomyosis, uterine fibroids, polyps, heavy menstrual bleeding and uterine malformations.

SEUD aims to improve disease management and reduce the impact on women’s lives through focused debate on disease awareness, pathogenesis, risk factors, diagnosis and medical/surgical treatments.

For more information about the Society of Endometriosis and Uterine Disorders (SEUD) visit their website.

Sign up to your FREE account today to receive the latest clinical insights, including congress news & coverage, links to the latest education relevant to your specialty, bookmarked articles, journals, and our monthly newsletter.

Please Reach out to find out more about our medical society partnerships.

Share this Article
Related Content In touchIME
touchIME
touchOUTCOMES: Introducing the Learner to Patient Impact Framework
Read Time: 2 mins

The 'Learner-to-Patient Impact Framework' (touchLPI) advances our holistic approach to delivering impactful education that has a positive impact on patient health.

touchIME
JAK inhibitors: A new player for hard-to-treat skin conditions
Read Time: 12 mins

In this episode, Dr William (Bill) Damsky discusses JAK inhibitors' journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

touchIME
Laying the groundwork for medical breakthroughs: The MPN-RC blueprint
Read Time: 12 mins

In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

Trending In touchIME:

touchOUTCOMES: Introducing the Learner to Patient Impact Framework
touchIME
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup